Global Bronchodilator

Bronchodilator Comprehensive Study by Type (Short-acting Bronchodilator, Long-acting Bronchodilator), Application (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Reactions, Others), Drug Class (Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Others), Route of Administration (Oral, Injectable, Nasa), Distribution Channel (Wholesale, Pharmacy Store, Online Store) Players and Region - Global Market Outlook to 2024

Bronchodilator Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Scope of the Study

Bronchodilator is the medicine used to relax muscle bands that tighten around airways, and this opens the airway and let’s more air move in and out of lungs, which helps to breathe easily. It is also used to remove mucus from lungs and open airways mean mucus can move more freely, it is more beneficial for asthma patients has led to significant growth of the market in the forecast period.

The market study is being classified by Type (Short-acting Bronchodilator and Long-acting Bronchodilator), by Application (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Reactions and Others) and major geographies with country level break-up.

GlaxoSmithKline plc (United Kingdom), Roche Holding AG (Switzerland), AstraZeneca plc (United Kingdom), C.H. Boehringer Sohn AG & Ko. KG (Germany), Amgen Inc. (United States), Kissei Pharmaceutical Co., Ltd. (Japan), Mitsubishi Tanabe Pharma Corporation (Japan), Sanofi S.A. (France), Theron Pharmaceuticals (United States) and Array BioPharma (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Kyowa Hakko Kirin Co., Ltd. (Japan), Verona Pharma (United Kingdom) and Takeda Pharmaceutical Co., Ltd. (Japan).

The Players having a strong hold in the market are GlaxoSmithKline plc, Roche Holding AG, and AstraZeneca plc. Research Analyst at AMA predicts that European Players will contribute to the maximum growth of Global Bronchodilator market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Bronchodilator market by Type, Application and Region.

On the basis of geography, the market of Bronchodilator has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing rate of Respiratory and Pulmonary Diseases such as COPD and Asthma
  • Increasing Awareness among Individuals in Developing Economies

Market Trend
  • Rising Demand for bronchodilator Drugs due to the Adoption of an Unhealthy Lifestyle

Restraints
  • Presence of Alternative Medicines

Opportunities
  • Rising Initiatives by Governments and Health Care Services


Market Leaders and their expansionary development strategies
On 9th November 2018, Theravance Biopharma, Inc. and Mylan N.V. have announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for YUPELRITM inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).



Key Target Audience
Bronchodilator Manufacturers, Healthcare Institutes, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors and Other

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Type
  • Short-acting Bronchodilator
  • Long-acting Bronchodilator
By Application
  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Allergic Reactions
  • Others
By Drug Class
  • Adrenergic Bronchodilators
  • Anticholinergic Bronchodilators
  • Others

By Route of Administration
  • Oral
  • Injectable
  • Nasa

By Distribution Channel
  • Wholesale
  • Pharmacy Store
  • Online Store

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing rate of Respiratory and Pulmonary Diseases such as COPD and Asthma
      • 3.2.2. Increasing Awareness among Individuals in Developing Economies
    • 3.3. Market Trends
      • 3.3.1. Rising Demand for bronchodilator Drugs due to the Adoption of an Unhealthy Lifestyle
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bronchodilator, by Type, Application, Drug Class, Route of Administration, Distribution Channel and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Bronchodilator (Value)
      • 5.2.1. Global Bronchodilator by: Type (Value)
        • 5.2.1.1. Short-acting Bronchodilator
        • 5.2.1.2. Long-acting Bronchodilator
      • 5.2.2. Global Bronchodilator by: Application (Value)
        • 5.2.2.1. Asthma
        • 5.2.2.2. Chronic Obstructive Pulmonary Disease
        • 5.2.2.3. Allergic Reactions
        • 5.2.2.4. Others
      • 5.2.3. Global Bronchodilator by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injectable
        • 5.2.3.3. Nasa
      • 5.2.4. Global Bronchodilator by: Distribution Channel (Value)
        • 5.2.4.1. Wholesale
        • 5.2.4.2. Pharmacy Store
        • 5.2.4.3. Online Store
      • 5.2.5. Global Bronchodilator Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Bronchodilator: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Holding AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. C.H. Boehringer Sohn AG & Ko. KG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Amgen Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kissei Pharmaceutical Co., Ltd. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mitsubishi Tanabe Pharma Corporation (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi S.A. (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Theron Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Array BioPharma (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Bronchodilator Sale, by Type, Application, Drug Class, Route of Administration, Distribution Channel and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Bronchodilator (Value)
      • 7.2.1. Global Bronchodilator by: Type (Value)
        • 7.2.1.1. Short-acting Bronchodilator
        • 7.2.1.2. Long-acting Bronchodilator
      • 7.2.2. Global Bronchodilator by: Application (Value)
        • 7.2.2.1. Asthma
        • 7.2.2.2. Chronic Obstructive Pulmonary Disease
        • 7.2.2.3. Allergic Reactions
        • 7.2.2.4. Others
      • 7.2.3. Global Bronchodilator by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injectable
        • 7.2.3.3. Nasa
      • 7.2.4. Global Bronchodilator by: Distribution Channel (Value)
        • 7.2.4.1. Wholesale
        • 7.2.4.2. Pharmacy Store
        • 7.2.4.3. Online Store
      • 7.2.5. Global Bronchodilator Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bronchodilator: by Type(USD Million)
  • Table 2. Bronchodilator Short-acting Bronchodilator , by Region USD Million (2013-2018)
  • Table 3. Bronchodilator Long-acting Bronchodilator , by Region USD Million (2013-2018)
  • Table 4. Bronchodilator: by Application(USD Million)
  • Table 5. Bronchodilator Asthma , by Region USD Million (2013-2018)
  • Table 6. Bronchodilator Chronic Obstructive Pulmonary Disease , by Region USD Million (2013-2018)
  • Table 7. Bronchodilator Allergic Reactions , by Region USD Million (2013-2018)
  • Table 8. Bronchodilator Others , by Region USD Million (2013-2018)
  • Table 9. Bronchodilator: by Route of Administration(USD Million)
  • Table 10. Bronchodilator Oral , by Region USD Million (2013-2018)
  • Table 11. Bronchodilator Injectable , by Region USD Million (2013-2018)
  • Table 12. Bronchodilator Nasa , by Region USD Million (2013-2018)
  • Table 13. Bronchodilator: by Distribution Channel(USD Million)
  • Table 14. Bronchodilator Wholesale , by Region USD Million (2013-2018)
  • Table 15. Bronchodilator Pharmacy Store , by Region USD Million (2013-2018)
  • Table 16. Bronchodilator Online Store , by Region USD Million (2013-2018)
  • Table 17. South America Bronchodilator, by Country USD Million (2013-2018)
  • Table 18. South America Bronchodilator, by Type USD Million (2013-2018)
  • Table 19. South America Bronchodilator, by Application USD Million (2013-2018)
  • Table 20. South America Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 21. South America Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 22. South America Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 23. Brazil Bronchodilator, by Type USD Million (2013-2018)
  • Table 24. Brazil Bronchodilator, by Application USD Million (2013-2018)
  • Table 25. Brazil Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 26. Brazil Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 27. Brazil Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 28. Argentina Bronchodilator, by Type USD Million (2013-2018)
  • Table 29. Argentina Bronchodilator, by Application USD Million (2013-2018)
  • Table 30. Argentina Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 31. Argentina Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 32. Argentina Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 33. Rest of South America Bronchodilator, by Type USD Million (2013-2018)
  • Table 34. Rest of South America Bronchodilator, by Application USD Million (2013-2018)
  • Table 35. Rest of South America Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 36. Rest of South America Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 37. Rest of South America Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 38. Asia Pacific Bronchodilator, by Country USD Million (2013-2018)
  • Table 39. Asia Pacific Bronchodilator, by Type USD Million (2013-2018)
  • Table 40. Asia Pacific Bronchodilator, by Application USD Million (2013-2018)
  • Table 41. Asia Pacific Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 42. Asia Pacific Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 43. Asia Pacific Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 44. China Bronchodilator, by Type USD Million (2013-2018)
  • Table 45. China Bronchodilator, by Application USD Million (2013-2018)
  • Table 46. China Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 47. China Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 48. China Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 49. Japan Bronchodilator, by Type USD Million (2013-2018)
  • Table 50. Japan Bronchodilator, by Application USD Million (2013-2018)
  • Table 51. Japan Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 52. Japan Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 53. Japan Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 54. India Bronchodilator, by Type USD Million (2013-2018)
  • Table 55. India Bronchodilator, by Application USD Million (2013-2018)
  • Table 56. India Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 57. India Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 58. India Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 59. South Korea Bronchodilator, by Type USD Million (2013-2018)
  • Table 60. South Korea Bronchodilator, by Application USD Million (2013-2018)
  • Table 61. South Korea Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 62. South Korea Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 63. South Korea Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 64. Taiwan Bronchodilator, by Type USD Million (2013-2018)
  • Table 65. Taiwan Bronchodilator, by Application USD Million (2013-2018)
  • Table 66. Taiwan Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 67. Taiwan Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 68. Taiwan Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 69. Australia Bronchodilator, by Type USD Million (2013-2018)
  • Table 70. Australia Bronchodilator, by Application USD Million (2013-2018)
  • Table 71. Australia Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 72. Australia Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 73. Australia Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 74. Rest of Asia-Pacific Bronchodilator, by Type USD Million (2013-2018)
  • Table 75. Rest of Asia-Pacific Bronchodilator, by Application USD Million (2013-2018)
  • Table 76. Rest of Asia-Pacific Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 77. Rest of Asia-Pacific Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 78. Rest of Asia-Pacific Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 79. Europe Bronchodilator, by Country USD Million (2013-2018)
  • Table 80. Europe Bronchodilator, by Type USD Million (2013-2018)
  • Table 81. Europe Bronchodilator, by Application USD Million (2013-2018)
  • Table 82. Europe Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 83. Europe Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 84. Europe Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 85. Germany Bronchodilator, by Type USD Million (2013-2018)
  • Table 86. Germany Bronchodilator, by Application USD Million (2013-2018)
  • Table 87. Germany Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 88. Germany Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 89. Germany Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 90. France Bronchodilator, by Type USD Million (2013-2018)
  • Table 91. France Bronchodilator, by Application USD Million (2013-2018)
  • Table 92. France Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 93. France Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 94. France Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 95. Italy Bronchodilator, by Type USD Million (2013-2018)
  • Table 96. Italy Bronchodilator, by Application USD Million (2013-2018)
  • Table 97. Italy Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 98. Italy Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 99. Italy Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 100. United Kingdom Bronchodilator, by Type USD Million (2013-2018)
  • Table 101. United Kingdom Bronchodilator, by Application USD Million (2013-2018)
  • Table 102. United Kingdom Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 103. United Kingdom Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 104. United Kingdom Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 105. Netherlands Bronchodilator, by Type USD Million (2013-2018)
  • Table 106. Netherlands Bronchodilator, by Application USD Million (2013-2018)
  • Table 107. Netherlands Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 108. Netherlands Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 109. Netherlands Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 110. Rest of Europe Bronchodilator, by Type USD Million (2013-2018)
  • Table 111. Rest of Europe Bronchodilator, by Application USD Million (2013-2018)
  • Table 112. Rest of Europe Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 113. Rest of Europe Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 114. Rest of Europe Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 115. MEA Bronchodilator, by Country USD Million (2013-2018)
  • Table 116. MEA Bronchodilator, by Type USD Million (2013-2018)
  • Table 117. MEA Bronchodilator, by Application USD Million (2013-2018)
  • Table 118. MEA Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 119. MEA Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 120. MEA Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 121. Middle East Bronchodilator, by Type USD Million (2013-2018)
  • Table 122. Middle East Bronchodilator, by Application USD Million (2013-2018)
  • Table 123. Middle East Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 124. Middle East Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 125. Middle East Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 126. Africa Bronchodilator, by Type USD Million (2013-2018)
  • Table 127. Africa Bronchodilator, by Application USD Million (2013-2018)
  • Table 128. Africa Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 129. Africa Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 130. Africa Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 131. North America Bronchodilator, by Country USD Million (2013-2018)
  • Table 132. North America Bronchodilator, by Type USD Million (2013-2018)
  • Table 133. North America Bronchodilator, by Application USD Million (2013-2018)
  • Table 134. North America Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 135. North America Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 136. North America Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 137. United States Bronchodilator, by Type USD Million (2013-2018)
  • Table 138. United States Bronchodilator, by Application USD Million (2013-2018)
  • Table 139. United States Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 140. United States Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 141. United States Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 142. Canada Bronchodilator, by Type USD Million (2013-2018)
  • Table 143. Canada Bronchodilator, by Application USD Million (2013-2018)
  • Table 144. Canada Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 145. Canada Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 146. Canada Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 147. Mexico Bronchodilator, by Type USD Million (2013-2018)
  • Table 148. Mexico Bronchodilator, by Application USD Million (2013-2018)
  • Table 149. Mexico Bronchodilator, by Drug Class USD Million (2013-2018)
  • Table 150. Mexico Bronchodilator, by Route of Administration USD Million (2013-2018)
  • Table 151. Mexico Bronchodilator, by Distribution Channel USD Million (2013-2018)
  • Table 152. Company Basic Information, Sales Area and Its Competitors
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Bronchodilator: by Type(USD Million)
  • Table 163. Bronchodilator Short-acting Bronchodilator , by Region USD Million (2019-2024)
  • Table 164. Bronchodilator Long-acting Bronchodilator , by Region USD Million (2019-2024)
  • Table 165. Bronchodilator: by Application(USD Million)
  • Table 166. Bronchodilator Asthma , by Region USD Million (2019-2024)
  • Table 167. Bronchodilator Chronic Obstructive Pulmonary Disease , by Region USD Million (2019-2024)
  • Table 168. Bronchodilator Allergic Reactions , by Region USD Million (2019-2024)
  • Table 169. Bronchodilator Others , by Region USD Million (2019-2024)
  • Table 170. Bronchodilator: by Route of Administration(USD Million)
  • Table 171. Bronchodilator Oral , by Region USD Million (2019-2024)
  • Table 172. Bronchodilator Injectable , by Region USD Million (2019-2024)
  • Table 173. Bronchodilator Nasa , by Region USD Million (2019-2024)
  • Table 174. Bronchodilator: by Distribution Channel(USD Million)
  • Table 175. Bronchodilator Wholesale , by Region USD Million (2019-2024)
  • Table 176. Bronchodilator Pharmacy Store , by Region USD Million (2019-2024)
  • Table 177. Bronchodilator Online Store , by Region USD Million (2019-2024)
  • Table 178. South America Bronchodilator, by Country USD Million (2019-2024)
  • Table 179. South America Bronchodilator, by Type USD Million (2019-2024)
  • Table 180. South America Bronchodilator, by Application USD Million (2019-2024)
  • Table 181. South America Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 182. South America Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 183. South America Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 184. Brazil Bronchodilator, by Type USD Million (2019-2024)
  • Table 185. Brazil Bronchodilator, by Application USD Million (2019-2024)
  • Table 186. Brazil Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 187. Brazil Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 188. Brazil Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 189. Argentina Bronchodilator, by Type USD Million (2019-2024)
  • Table 190. Argentina Bronchodilator, by Application USD Million (2019-2024)
  • Table 191. Argentina Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 192. Argentina Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 193. Argentina Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 194. Rest of South America Bronchodilator, by Type USD Million (2019-2024)
  • Table 195. Rest of South America Bronchodilator, by Application USD Million (2019-2024)
  • Table 196. Rest of South America Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 197. Rest of South America Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 198. Rest of South America Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 199. Asia Pacific Bronchodilator, by Country USD Million (2019-2024)
  • Table 200. Asia Pacific Bronchodilator, by Type USD Million (2019-2024)
  • Table 201. Asia Pacific Bronchodilator, by Application USD Million (2019-2024)
  • Table 202. Asia Pacific Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 203. Asia Pacific Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 204. Asia Pacific Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 205. China Bronchodilator, by Type USD Million (2019-2024)
  • Table 206. China Bronchodilator, by Application USD Million (2019-2024)
  • Table 207. China Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 208. China Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 209. China Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 210. Japan Bronchodilator, by Type USD Million (2019-2024)
  • Table 211. Japan Bronchodilator, by Application USD Million (2019-2024)
  • Table 212. Japan Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 213. Japan Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 214. Japan Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 215. India Bronchodilator, by Type USD Million (2019-2024)
  • Table 216. India Bronchodilator, by Application USD Million (2019-2024)
  • Table 217. India Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 218. India Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 219. India Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 220. South Korea Bronchodilator, by Type USD Million (2019-2024)
  • Table 221. South Korea Bronchodilator, by Application USD Million (2019-2024)
  • Table 222. South Korea Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 223. South Korea Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 224. South Korea Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 225. Taiwan Bronchodilator, by Type USD Million (2019-2024)
  • Table 226. Taiwan Bronchodilator, by Application USD Million (2019-2024)
  • Table 227. Taiwan Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 228. Taiwan Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 229. Taiwan Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 230. Australia Bronchodilator, by Type USD Million (2019-2024)
  • Table 231. Australia Bronchodilator, by Application USD Million (2019-2024)
  • Table 232. Australia Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 233. Australia Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 234. Australia Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 235. Rest of Asia-Pacific Bronchodilator, by Type USD Million (2019-2024)
  • Table 236. Rest of Asia-Pacific Bronchodilator, by Application USD Million (2019-2024)
  • Table 237. Rest of Asia-Pacific Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 238. Rest of Asia-Pacific Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 239. Rest of Asia-Pacific Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 240. Europe Bronchodilator, by Country USD Million (2019-2024)
  • Table 241. Europe Bronchodilator, by Type USD Million (2019-2024)
  • Table 242. Europe Bronchodilator, by Application USD Million (2019-2024)
  • Table 243. Europe Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 244. Europe Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 245. Europe Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 246. Germany Bronchodilator, by Type USD Million (2019-2024)
  • Table 247. Germany Bronchodilator, by Application USD Million (2019-2024)
  • Table 248. Germany Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 249. Germany Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 250. Germany Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 251. France Bronchodilator, by Type USD Million (2019-2024)
  • Table 252. France Bronchodilator, by Application USD Million (2019-2024)
  • Table 253. France Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 254. France Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 255. France Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 256. Italy Bronchodilator, by Type USD Million (2019-2024)
  • Table 257. Italy Bronchodilator, by Application USD Million (2019-2024)
  • Table 258. Italy Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 259. Italy Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 260. Italy Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 261. United Kingdom Bronchodilator, by Type USD Million (2019-2024)
  • Table 262. United Kingdom Bronchodilator, by Application USD Million (2019-2024)
  • Table 263. United Kingdom Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 264. United Kingdom Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 265. United Kingdom Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 266. Netherlands Bronchodilator, by Type USD Million (2019-2024)
  • Table 267. Netherlands Bronchodilator, by Application USD Million (2019-2024)
  • Table 268. Netherlands Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 269. Netherlands Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 270. Netherlands Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 271. Rest of Europe Bronchodilator, by Type USD Million (2019-2024)
  • Table 272. Rest of Europe Bronchodilator, by Application USD Million (2019-2024)
  • Table 273. Rest of Europe Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 274. Rest of Europe Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 275. Rest of Europe Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 276. MEA Bronchodilator, by Country USD Million (2019-2024)
  • Table 277. MEA Bronchodilator, by Type USD Million (2019-2024)
  • Table 278. MEA Bronchodilator, by Application USD Million (2019-2024)
  • Table 279. MEA Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 280. MEA Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 281. MEA Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 282. Middle East Bronchodilator, by Type USD Million (2019-2024)
  • Table 283. Middle East Bronchodilator, by Application USD Million (2019-2024)
  • Table 284. Middle East Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 285. Middle East Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 286. Middle East Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 287. Africa Bronchodilator, by Type USD Million (2019-2024)
  • Table 288. Africa Bronchodilator, by Application USD Million (2019-2024)
  • Table 289. Africa Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 290. Africa Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 291. Africa Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 292. North America Bronchodilator, by Country USD Million (2019-2024)
  • Table 293. North America Bronchodilator, by Type USD Million (2019-2024)
  • Table 294. North America Bronchodilator, by Application USD Million (2019-2024)
  • Table 295. North America Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 296. North America Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 297. North America Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 298. United States Bronchodilator, by Type USD Million (2019-2024)
  • Table 299. United States Bronchodilator, by Application USD Million (2019-2024)
  • Table 300. United States Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 301. United States Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 302. United States Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 303. Canada Bronchodilator, by Type USD Million (2019-2024)
  • Table 304. Canada Bronchodilator, by Application USD Million (2019-2024)
  • Table 305. Canada Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 306. Canada Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 307. Canada Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 308. Mexico Bronchodilator, by Type USD Million (2019-2024)
  • Table 309. Mexico Bronchodilator, by Application USD Million (2019-2024)
  • Table 310. Mexico Bronchodilator, by Drug Class USD Million (2019-2024)
  • Table 311. Mexico Bronchodilator, by Route of Administration USD Million (2019-2024)
  • Table 312. Mexico Bronchodilator, by Distribution Channel USD Million (2019-2024)
  • Table 313. Research Programs/Design for This Report
  • Table 314. Key Data Information from Secondary Sources
  • Table 315. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bronchodilator: by Type USD Million (2013-2018)
  • Figure 5. Global Bronchodilator: by Application USD Million (2013-2018)
  • Figure 6. Global Bronchodilator: by Route of Administration USD Million (2013-2018)
  • Figure 7. Global Bronchodilator: by Distribution Channel USD Million (2013-2018)
  • Figure 8. South America Bronchodilator Share (%), by Country
  • Figure 9. Asia Pacific Bronchodilator Share (%), by Country
  • Figure 10. Europe Bronchodilator Share (%), by Country
  • Figure 11. MEA Bronchodilator Share (%), by Country
  • Figure 12. North America Bronchodilator Share (%), by Country
  • Figure 13. Global Bronchodilator share by Players 2018 (%)
  • Figure 14. Global Bronchodilator share by Players (Top 3) 2018(%)
  • Figure 15. Global Bronchodilator share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2018
  • Figure 19. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Roche Holding AG (Switzerland) Revenue: by Geography 2018
  • Figure 21. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. AstraZeneca plc (United Kingdom) Revenue: by Geography 2018
  • Figure 23. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 24. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue: by Geography 2018
  • Figure 25. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Amgen Inc. (United States) Revenue: by Geography 2018
  • Figure 27. Kissei Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Kissei Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2018
  • Figure 29. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue: by Geography 2018
  • Figure 31. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi S.A. (France) Revenue: by Geography 2018
  • Figure 33. Theron Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 34. Theron Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 35. Array BioPharma (United States) Revenue, Net Income and Gross profit
  • Figure 36. Array BioPharma (United States) Revenue: by Geography 2018
  • Figure 37. Global Bronchodilator: by Type USD Million (2019-2024)
  • Figure 38. Global Bronchodilator: by Application USD Million (2019-2024)
  • Figure 39. Global Bronchodilator: by Route of Administration USD Million (2019-2024)
  • Figure 40. Global Bronchodilator: by Distribution Channel USD Million (2019-2024)
  • Figure 41. South America Bronchodilator Share (%), by Country
  • Figure 42. Asia Pacific Bronchodilator Share (%), by Country
  • Figure 43. Europe Bronchodilator Share (%), by Country
  • Figure 44. MEA Bronchodilator Share (%), by Country
  • Figure 45. North America Bronchodilator Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Roche Holding AG (Switzerland)
  • AstraZeneca plc (United Kingdom)
  • C.H. Boehringer Sohn AG & Ko. KG (Germany)
  • Amgen Inc. (United States)
  • Kissei Pharmaceutical Co., Ltd. (Japan)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Sanofi S.A. (France)
  • Theron Pharmaceuticals (United States)
  • Array BioPharma (United States)
Additional players considered in the study are as follows:
Kyowa Hakko Kirin Co., Ltd. (Japan) , Verona Pharma (United Kingdom) , Takeda Pharmaceutical Co., Ltd. (Japan)
Select User Access Type

Key Highlights of Report


Nov 2019 212 Pages 73 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bronchodilator Quantitative research analysis
Global Bronchodilator Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Bronchodilator Report?

Have a Query? Click Here

Other Related Reports

Acne Vulgaris Comprehensive Study by Application (Hospitals, Clinics, Others), Therapy Type (Systemic Therapy, Harmonal Therapy, Topical Combination Therapy, Others), Type of Lesions (Non inflammator...
$ 3500
Myasthenia Gravis Comprehensive Study by Type (Congenital Hereditary, Autoimmune Disease), Application (Hospital, Medical Clinical Research Center, Others), Treatment type (Therapeutic approach, Medi...
$ 3750
Transdermal Skin Patches Comprehensive Study by Type (Drug in Adhesive, Matrix, Reservoir, Vapor, Other), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End Use (Hospital Ph...
$ 3450
Kidney Cancer Drugs Comprehensive Study by Type (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus)...
$ 3650
Obesity Treatment Comprehensive Study by Application (Children, Adults), Drugs (Combination Drugs, Appetite Suppressants, Malabsorption, Satiety), Treatment (Medication, Surgery, Lifestyle Changes), ...
$ 3750
Plant Sterol Esters Comprehensive Study by Type (Oil, Powder), End Users (Food & Beverages, Dairy Products, Pharmaceutical, Cosmetics) Players and Region - Global Market Outlook to 2026
$ 3500